Highlights Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 08/12/2025 GMT			5-day change	1st Jan Change
26.12 ^USD	-7.15%		-2.68%	-19.73%

12-08	UBS Adjusts Legend Biotech Price Target to $48 From $54, Maintains Buy Rating	MT
12-06	Legend Biotech highlights new Carvykti® data in multiple myeloma and first-in-human results from novel CAR-T platform in non-Hodgkin lymphoma at ASH 2025	RE

Highlights

Legend Biotech Corporation Celebrates Official Opening of New Cell Therapy Research and Development Facility in Philadelphia	11-13	CI
Legend Biotech Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	11-12	CI
Legend Biotech Q3 Adjusted Loss Narrows, Revenue Rises	11-12	MT
Legend Biotech Q3 revenue slightly misses estimates	11-12	RE
Earnings Flash (LEGN) Legend Biotech Corporation Reports Q3 Revenue $272.3M, vs. FactSet Est of $274.4M	11-12	MT
Earnings Flash (LEGN) Legend Biotech Corporation Posts Q3 Adjusted Loss $0.05 per Share	11-12	MT
GenScript Associate Books $524 Million in Q3 CARVYKTI Sales	10-15	MT
Legend Biotech Corporation Announces U.S. Fda Approves Label Updates for Carvykti® Car-T Cell Therapy to Include Overall Survival Data	10-14	CI
The Presidential Whiplash Index	10-13
Legend Biotech USA Inc. Enters into Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc	10-07	CI
Legend Biotech Said to Consider Second Listing Outside US	09-05	MT
Legend Biotech Said to Consider Second Listing Outside US, Bloomberg Reports	09-05	MT
Sector Update: Health Care Stocks Rise Premarket Monday	08-11	MT
Legend Biotech Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	08-11	CI
Correction: Earnings Flash (LEGN) Legend Biotech Corporation Posts Q2 Adjusted EPS $0.03 per Share	08-11	MT
Legend Biotech Swings to Q2 Adjusted Earnings, Revenue Rises	08-11	MT
Legend Biotech Q2 collaboration revenue up on CARVYKTI sales	08-11	RE
Earnings Flash (LEGN) Legend Biotech Corporation Reports Q2 Revenue $255.1M, vs. FactSet Est of $228.0M	08-11	MT
Earnings Flash (LEGN) Legend Biotech Corporation Posts Q2 Loss $0.34 per Share, vs. FactSet Est of $-0.17	08-11	MT
Legend Biotech Provides Update on REMS for Currently Approves BCMA- and CD19-Directed Autologous Chimeric Antigen Receptor T Cell Immunotherapies	06-30	CI
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)	06-27	RE
Legend Biotech Corporation Unveils 5-Year Survival Data for Carvykti®? in Multiple Myeloma At 2025 Asco Annual Meeting	06-03	CI
Legend Biotech Corporation to Present New Data on Carvykti for Patients with Multiple Myeloma At 2025 Asco and Eha Annual Meeting	05-23	CI
Legend Biotech Corporation Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT	05-22	CI
Legend Biotech Shares Have 'Meaningful Upside' With Continued Execution, RBC Says	05-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Highlights

Filters